https://www.healthcaretribunefrance.com/article/906895935-nanobiotix-annonce-de-nouvelles-donn-es-pr-cliniques-d-montrant-une-am-lioration-de-la-biodisponibilit-syst-mique-et-la-r-duction-de-la-toxicit-pour Healthcare Tribune France en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix annonce de nouvelles données précliniques démontrant une amélioration de la biodisponibilité systémique et la réduction de la toxicité pour des immunothérapies à ADN delivrées par LNP après traitement avec sa technologie de… https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906896055-nanobiotix-announces-new-preclinical-data-supporting-improved-systemic-bioavailability-and-reduced-toxicity-for-lnp-delivered-dna-immunotherapy-after Healthcare Tribune France en PressRelease 2026-04-20T06:30:00+00:00 Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology https://ml.globenewswire.com/media/36fb7b98-27d7-46cb-b989-fa31626657b8/small/nanobiotix-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906891437-reminder-last-exercise-day-for-nicox-june-2024-warrants-is-june-19-2026 Healthcare Tribune France en PressRelease 2026-04-20T05:30:00+00:00 Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/logo-png.png https://www.healthcaretribunefrance.com/article/906891441-rappel-le-dernier-jour-d-exercice-pour-les-bons-de-souscription-d-actions-bsa-nicox-de-juin-2024-est-le-19-juin-2026 Healthcare Tribune France en PressRelease 2026-04-20T05:30:00+00:00 Rappel : le dernier jour d’exercice pour les Bons de Souscription d’Actions (BSA) Nicox de juin 2024 est le 19 juin 2026 https://ml-eu.globenewswire.com/media/c4c68e53-e467-4048-b580-d1596c4d6d8e/small/ https://www.healthcaretribunefrance.com/article/906534059-ascendo-ai-brings-ai-resolve-to-google-cloud-marketplace Healthcare Tribune France en PressRelease 2026-04-18T16:44:15+00:00 Ascendo AI Brings AI Resolve to Google Cloud Marketplace https://www.healthcaretribunefrance.com/article/906501406-press-release-escmid-sanofi-s-nuvaxovid-covid-19-vaccine-showed-better-tolerability-than-mnexspike-in-head-to-head-study Healthcare Tribune France en PressRelease 2026-04-18T10:00:00+00:00 Press Release: ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg https://www.healthcaretribunefrance.com/article/906501531-communiqu-de-presse-escmid-le-nuvaxovid-vaccin-contre-la-covid-19-de-sanofi-a-montr-une-meilleure-tol-rance-que-le-mnexspike-dans-une-tude Healthcare Tribune France en PressRelease 2026-04-18T10:00:00+00:00 Communiqué de presse : ESCMID : Le Nuvaxovid, vaccin contre la COVID-19 de Sanofi, a montré une meilleure tolérance que le mNEXSPIKE dans une étude comparative directe   https://ml-eu.globenewswire.com/media/06da731a-67a1-4258-939f-6ef0531ee3bf/small/sanofi-new-logo-jpg.jpg